At what enterprise value was CEVA SANTE ANIMALE acquired in 2020?

During the acquisition of CEVA SANTE ANIMALE by TETHYS INVEST / PSP INVESTMENTS / MITSUI & CO in 2020, the transaction's Enterprise Value is estimated to be in the range of 3b - 100b EUR.

What was the EV/EBITDA of CEVA SANTE ANIMALE when it was acquired by TETHYS INVEST / PSP INVESTMENTS / MITSUI & CO?

The estimated EV/EBITDA multiple for CEVA SANTE ANIMALE is in the range of 15x - 25x.

What was the revenue of CEVA SANTE ANIMALE at the time of the deal?

The revenue of CEVA SANTE ANIMALE at the time of the deal is estimated to be in the range of 750M - 1.3b EUR.

What was the EBITDA of CEVA SANTE ANIMALE during the acquisition?

CEVA SANTE ANIMALE's EBITDA is estimated to be in the range of 250M - 500M EUR.

How is the data for the CEVA SANTE ANIMALE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the CEVA SANTE ANIMALE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/ceva-sante-animale-sengage-dans-un-jumbo-lbo-historique-1169040

← DATABASE

Home Database Healthcare & PharmaCEVA SANTE ANIMALE

02/2020

CEVA SANTE ANIMALE acquired by TETHYS INVEST / PSP INVESTMENTS / MITSUI & CO

FRANCE Life Sciences / Animal Health EV 3b - 100b EUR

Context

Ceva Sante Animale completed a historic "Jumbo LBO". This transaction allowed the management team (800+ executives) to retain over 50% of the capital—a record for a deal of this size in France (comparable only to the Legrand buyout in 2002). Four new long-term investors joined the "Friends of Ceva" consortium: Tethys Invest, PSP, Mitsui, and Klocke. Historical investors, led by Temasek, significantly reinvested their proceeds.

It is worth noting that the fund Institut Merieux / Sagard / Sofiproteol took control of Ceva Sante Animale through an LBO in 2014.

CEVA SANTE ANIMALE, which reported an EBITDA margin of in 2019, is valued in this transaction at an EV/EBITDA multiple of , representing a level the average currently observed in the Healthcare & Pharma sector (15.9x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Ceva is the 5th largest animal health company in the world. Headquartered in Libourne, it employs 7,000 people in 47 countries. The group balances its activity between preventive medicine (vaccines) and pharmaceutical products for poultry, swine, ruminants, and pets (30% of sales). It invests ~10% of revenue in R&D.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Other operations with CEVA SANTE ANIMALE

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
04/2025	INSTITUT MERIEUX / ARCHIMED	CEVA SANTE ANIMALE	FRANCE	Animal Health
09/2014	INSTITUT MERIEUX / SAGARD / SOFIPROTEOL	CEVA SANTE ANIMALE	FRANCE	Animal Health

REFERENCES

Valuation range: EV 3b - 100b EUR

Revenue range: 750M - 1.3b EUR

EBITDA range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of CEVA SANTE ANIMALE by TETHYS INVEST / PSP INVESTMENTS / MITSUI & CO are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: ceva sante animale

Acquirer: mitsui & co / psp investments / tethys invest